November 11th, 2005 MOLOGEN: MIDGE-TH1 patent will be granted in Europe

Ad-hoc Release  
November 10th, 2005 MOLOGEN submits report on third quarter:
The course is set on a positive future

Ad-hoc Release  
October 12th, 2005 MOLOGEN AG raises funds for clinical trials by increasing share capital

Ad-hoc Release  
September 30th, 2005 MOLOGEN AG strengthened liquidity by successful capital increase

Ad-hoc Release  
September 22nd, 2005 MOLOGEN receives manufacturing authorisation for a DNA vaccine

Ad-hoc Release  
August 11th, 2005 MOLOGEN AG

MOLOGEN strengthens basis for positive business development with non-recurring expenditure. Positive prognosis for the remaining year

Ad-hoc Release  I  Press Release  I  Half-year Report 2005 (pdf)
July 21th, 2005 MOLOGEN AG adapts executive board structure to future growth
Company expands board to three members, appoints new chief financial officer

Ad-hoc Release
June 14th, 2005 MOLOGEN AG

Press Release
Annual meeting 2005 - presentation of the executive board >pdf
May 12th, 2005

MOLOGEN announces solid cash position and good outlook for 2005

Press Release
Interim Report 1st Quarter 2005 (pdf)
April 28th, 2005 MOLOGEN Successfully Placed Capital Increase

Ad-hoc announcement
April 5th, 2005 MOLOGEN obtains order for the first cell and gene therapy center in Saudi Arabia and receives down payment

Ad-hoc announcement
March 30th, 2005 MOLOGEN: Successful turn around in 2004, good order situation for 2005

Press Release
Consolidated Financial Statements 2004, preliminary (pdf)
March 17th, 2005

MOLOGEN AG: Important Technology Patent Granted for the USA

Press Release
January 21st, 2005

Sal. Oppenheim is designated sponsor of MOLOGEN shares

Press Release
December 29th, 2004

MOLOGEN: Executive Board orients towards new commercial tasks

Press Release
December 22nd, 2004

MOLOGEN and IDRI sign Collaboration Agreement

Press Release
December 20th, 2004 MOLOGEN has placed Capital Increase

Ad-hoc announcement
November 11th, 2004 MOLOGEN AG: Strong Business Performance - Sales Target Figures exceeded

Press Release
Report on the first nine months 2004 (pdf)
November 1st, 2004

MOLOGEN AG: Patent for MIDGE against Chronical Pain will be granted

Press Release
October 11th, 2004

Cooperating for a New Tuberculosis Vaccine

Max Planck Institute for Infection Biology and MOLOGEN initiate development of a new tuberculosis subunit vaccine

Press Release
October 5th, 2004

MOLOGEN receives Grant for Cell-based Cancer Therapy

Press Release
August 27th, 2004

MOLOGEN has placed Capital Increase

Ad-hoc-announcement
August 26th, 2004

MOLOGEN in China: Joint Venture against Infectious Diseases

Press Release
August 19th, 2004

MOLOGEN AG: Ground-breaking Contract with Arabian Partners Signed

Ad-hoc-announcement
August 12th, 2004 Business transaction increases revenues significantly

Interim report of MOLOGEN AG as at 30 June 2004 (pdf)
July 12th, 2004

MOLOGEN Licenses DNABarrier to Chinese Biotech-Corporation

Ad-hoc-announcement
July 1st, 2004

MOLOGEN: Deal with Arabian Partners Delayed

Press Release
June 11th, 2004

MOLOGEN: Scientists report at Conferences in the US and South Korea

Press Release
June 3rd, 2004

MOLOGEN AG: Large block trade of shares

Press Release
May 28th, 2004

General Meeting of MOLOGEN AG:
Prospective Major Order, Replacements in the Supervisory Board

Press Release
May 19th, 2004

MOLOGEN in China: The first Joint Venture for Gene Therapy against Cancer

Press Release
May 14th, 2004 MOLOGEN confirms forecast despite a weak first quarter

Interim report of MOLOGEN AG as at 31 March 2004 (pdf)
April 28th, 2004 Public support for DNAShield project
MOLOGEN received the official notification of grants for the DNAShield during the 6th Biotechnology Days in Jena on April, 26 (see our press release of April, 7). MOLOGEN is one of the first six companies, which receive support by the newly founded BioChancePLUS programme. The Federal Ministry of Education and Research through BioChancePLUS supports small and medium-sized biotech companies. A total of 0.26 Mill. EUR will be at MOLOGEN disposal within the next 24 months, with a maximal project volume of 0.86 Mill. EUR.
 
 
Research study on MOLOGEN: Rating neutral
Yesterday MOLOGEN presented itself on the Spring Conference for Small and Mid Caps in Frankfurt. Accompanying this presentation, German Business Concepts published a brief research report on MOLOGEN. Study (only available in German)
 
 
Annual Report 2003
For the first time MOLOGEN published its annual report bilingual, in German and English.
> Investor Relations > Annual Reports
 
April 27th, 2004

MOLOGEN and MEBO: Joining Forces to Treat Cancer

Press Release
April 7th, 2004

MOLOGEN receives promise of subsidies from BioChancePLUS Programme

Press Release
March 31, 2004 2003 Annual Report: MOLOGEN reduced losses

Press Release
Annual Report 2003
February 5th ,
2004		 MOLOGEN technology for defence against infections positively appraised in China

Press Release
January 15th ,
2004		 Important additions to the patent portfolio of MOLOGEN AG

Press Release
November 13th ,
2003		 Restructuring complete, production capacity to be expanded

Interim Report of MOLOGEN AG as of September 30th, 2003 (pdf)
September 15th ,
2003		 Merger with Subsidiaries Effective

Press Release
August 15th ,
2003		 Mologen starts Marketing Campaign
Significantly decreased Deficit and Outflow of Funds

Interim Report of Mologen Holding AG as of June 30th, 2003 (pdf)
July 3rd ,
2003		 Mologen´s dSLIM Technology evaluated in Clinical Phase 2 Study
against Colorectal Carcinoma

Press Release
July 1st ,
2003		 Mologen Starts Clinical Trial of a MIDGE®-based DNA Vaccine
against Leishmaniasis in Dogs

Press Release
May 16th ,
2003		 Press release for Mologen Holding AG for the
5th annual general meeting on May 15, 2003
Press Release
May 15th ,
2003		 Mologen reduces losses by half

Interim Report of Mologen Holding AG as at 31 May 2002 (pdf)
April 9th ,
2003		 Mologen Presents its Annual Financial Statements and Annual Report for 2002
Press Release

Please download our Annual Report 2002 from: Investor Relations > Annual Report
January 24th ,
2003		 Mologen Downsizes Executive Board
Press Release
January 9th ,
2003		 New Member of the Supervisory Board as of January 1, 2003
Press Release
December 20th ,
2002		 Mologen announces capital increase
Press Release
December 17th ,
2002		 Research Award for University Ophthalmology Department and Mologen
Press Release
December 4th ,
2002		 Successful Vaccination against Parasitic Disease with MIDGE
Press Release
November 20th ,
2002		 Interim Report of Mologen Holding AG as at 30 September 2002 (pdf)
November 13th ,
2002		 Mologen Holding AG Merges with Subsidiaries
Press Release
November 11th ,
2002		 Mologen Presents New Results at an International Conference in Edinburgh
Press Release
October 28th ,
2002		 Further Important Patent Granted in the USA
Press Release
October 23rd ,
2002		 MIDGE Basic Patent Granted in the USA
Press Release
September 9th ,
2002		 A Large Pharmaceutical Company is Testing Mologen Vaccines
Press Release
September 6th ,
2002		 Half Year Report 2002 (pdf)
July 24th ,
2002		 Mologen to Rise in the Regulated Market:
Shares to be Quoted from Monday on the Frankfurt Stock Exchange
Ad-hoc Press Release
June 24th ,
2002		 MIDGE: Novel Findings
Research team presents new data on superiority and safety of Mologen technology at the US Gene Therapy Congress
Press Release
May 17th ,
2002		 4th Ordinary Annual General Meeting of Shareholders
Press Release Presentation
May 7th ,
2002		 Mologen's presentation at the DVFA Biotech Forum
Presentation Download Realplayer
April 9th ,
2002		 Mologen Presents Financial Statements and Annual Report for 2001
Press Release
March 14th ,
2002		 Mologen Confirms its Plans to Achieve a Positive EBIT in 2003
Press Release
March 5th ,
2002		 Mologen Announces Provisional Figures for 2001 as Well as Dates for 2002
Press Release
February 25th ,
2002		 Mologen Looks Back on Successful Research and Development in 2001
Press Release
January 28th,
2002		 Mologen und Schering develop cell therapies using MIDGE technology
Press Release
January 2nd,
2002		 Top Manager joins Mologen's Board of Directors
Press Release
December 20th,
2001		 Mologen to Switch in 2002 to the Regulated Market
Press Release
December 17th,
2001
MIDGE Basic Patent Is Final in Europe after Expiry of Time Limit for Filing Notice of Opposition
Press Release
November 30th,
2001
Board of directors authorized to buy back shares
Press Release
October 15th,
2001
Mologen on Expansion Course: More Space for Product Development and MIDGE Production
Press Release
October 9th,
2001
Mologen and Soft Gene present innovative software technology for biotechnological research and development at the Biotechnica trade fair in Hanover
Press Release
June 26th,
2001
Mologen launches in the USA new product for the R&D markets
Press Release
April 25th,
2001
April 10th,
2001
Mologen: New acquisition and new co-operation
Ad-hoc Press release
Press release
February 21st,
2001		 Mologen files patent application for gene-modified cell vaccine
Ad-hoc Press release
Press release
Scientific press release
December 21st,
2000		 MIDGE Patent granted by European Patent Office
Ad-hoc Press release
September 25th,
2000		 Mologen executes three-for-one stock split
Press release
August 31st,
2000		 Effective treatment of corneal graft rejection
Press release
August 18th,
2000		 Successful vaccination experiment against the feline immunodeficiency virus FIV
Press release
June 27th,
2000		 Mologen announces capital increase
Ad-hoc press release
Press release
April 26th,
2000		 Mologen's 1999 revenue increase 26%
Consolidated statements of income
Consolidated Balance sheet
March 30th,
2000		 Mologen launches lymphoma phase II/III clinical trial
February 8th,
2000		 Follow-up report of SES Research GmbH about Mologen
Report as Webpage       Report for Acrobat Reader        Request the hardcopy
November 24th,
1999		 Multinational group of investors put their money in Mologen's proprietary MIDGEtechnology.
Study confirms safety of MIDGE technology
July 29th,
1999		 Breakthrough for Mologen AG: Rhône-Poulenc uses Mologen technology in clinical trial for therapy of colon carcinoma
December 9th,
1998		 Mologen announces partnership with VIRBAC
September 4th,
1998		 Mologen announces successful development and issuance of patentability of key technologies
Two months after her IPO, Mologen Holding AG announces that some vital development targets have been met earlier than anticipated.
June 22nd,
1998		 Successful first public offering of a conceptual biotechnology firm in Germany by Mologen
Shares of Mologen Holding AG are traded on the Berlin exchange since Monday, June 22nd, 1998. The IPO generated about 10 mDM for the firm, its public valuation is now at about 67 mDM.